J Gastric Cancer 2018 Sep183218229 httpsdoiorg105230jgc201818e23 pISSN 2093582XeISSN 20935641 Original Article Preoperative Nodal 18FFDG Avidity Rather Primary Tumor Avidity Determines Prognosis Patients Advanced Gastric Cancer Hyun Woo Kwon 1 Sungeun Kim 1 Liang An 2 Hye Ryeong Kwon 1 Sungsoo Park 2 1Department Nuclear Medicine Korea University Anam Hospital Seoul Korea 2Department Surgery Korea University Anam Hospital Seoul Korea Received May 1 2018 Revised Jul 15 2018 Accepted Jul 23 2018 Correspondence Sungeun Kim Department Nuclear Medicine Korea University Anam Hospital Korea University College Medicine 73 Inchonro Seongbukgu Seoul 02841 Korea Email seiongkoreaackr Sungsoo Park Department Surgery Korea University Anam Hospital Korea University College Medicine 73 Inchonro Seongbukgu Seoul 02841 Korea Email kugspsskoreaackr Sungsoo Park Sungeun Kim equally contributed work Copyright 2018 Korean Gastric Cancer Association This Open Access article distributed terms Creative Commons Attribution NonCommercial License https creativecommonsorglicensesbync40 permits unrestricted noncommercial use distribution reproduction medium provided original work properly cited ORCID iDs Hyun Woo Kwon httpsorcidorg000000020597837X Liang An httpsorcidorg0000000254667834 Hye Ryeong Kwon httpsorcidorg0000000240608294 Sungsoo Park httpsorcidorg0000000217798683 ABSTRACT Purpose This study investigated metabolic avidity primary tumors metastatic lymph nodes LNs measured 18Ffluorodeoxyglucose 18FFDG positron emission tomographycomputed tomography PETCT related survival surgery patients advanced gastric cancer AGC Materials Methods One sixtyeight patients AGC underwent preoperative 18FFDG PETCT curative resection included The 18FFDG avidity primary gastric tumor LNs determined quantitatively qualitatively The diagnostic performance 18FFDG PETCT calculated prognostic significance 18FFDG avidity recurrencefree survival RFS overall survival OS assessed Results In 51 304 patients experienced recurrence 32 190 died followup median followup duration 35 months range 381 months 119 708 33 196 patients showed 18FFDGavid primary tumors LNs respectively 18FFDG PET CT showed high sensitivity 738 detection advanced pathologic T pT 3 stage high specificity 922 detection advanced pN 2 stage 18FFDG avidity LNs significantly associated RFS P0012 primary tumors significance P0532 Univariate multivariate analyses revealed 18FFDG avidity LNs independent prognostic factor RFS hazard ratio2068 P0029 Conclusions 18FFDG avidity LNs independent prognostic factor predicting RFS Preoperative 18FFDG PETCT determine risk prognosis patients AGC curative resection Keywords Gastric cancer 18Ffluorodeoxyglucose Positron Emission Tomography Computed Tomography Recurrence INTRODUCTION Advanced gastric cancer AGC common malignancies resulting cancer related deaths Asian populations 13 Radical surgery standard treatment option patients resectable disease prognosis remains poor 5year survival approximately 30 3 Recurrence curative surgery occurs 1254 cases main cause cancerrelated death 4 Hence stratifying patients risk httpsjgconlineorg 218 LN FDG Avidity AGC Patients Sungeun Kim httpsorcidorg0000000233920263 Funding This work supported Korea University Grant Author Contributions Conceptualization PS KS Data curation KHW AL KHR PS Investigation KHW KHR Project administration PS KS Writing original draft KHW Writing review editing PS KS Conflict Interest No potential conflict relevant article reported prediction prognosis key issues postoperative management AGC patients The tumor node metastasis TNM classification American Joint Committee Cancer AJCC predict patients prognoses However conventional clinicopathological approach adequately represent complexity gastric cancer biology 56 Current guidelines staging AGC include gastrofiberscopy contrastenhanced computed tomography CECT thorax abdomen pelvis laparoscopy 18Ffluorodeoxyglucose 18FFDG positron emission tomographycomputed tomography PETCT preferred evaluate metastatic disease 78 18FFDG PETCT shown useful AGC patients aspects 18FFDG PETCT determine operability locally advanced gastric cancer 9 facilitate detection recurrence followup surgery 1011 Several studies shown usefulness 18FFDG PETCT prognosis AGC patients undergoing chemotherapy 1213 However independent role preoperative 18FFDG PETCT AGC needs investigated Lymph node LN metastasis substantial factor staging prognosis patients AGC 14 Although 18FFDG PETCT low diagnostic sensitivity LN metastasis evaluation LN metabolism useful predict prognosis 15 The advantage 18FFDG PETCT simultaneous assessment comparison metabolism primary tumors metastatic LNs provide prognostic information 1617 A comprehensive evaluation metabolic aggressiveness metastatic LNs preoperative setting potential biomarker AGC In study evaluated metabolic characteristics primary tumors andor metastatic LNs compared survival data surgery patients AGC determine clinical impact preoperative 18FFDG PETCT MATERIALS AND METHODS Patients We analyzed medical records consecutive AGC patients hospital July 2010 December 2014 Among 168 patients AGC underwent curative surgical resection enrolled study The inclusion criteria 1 initial diagnosis gastric cancer 2 preoperative staging 18FFDG PETCT hospital 3 pathologic staging T2T4 4 histological type common epithelial tumor according Japanese Gastric Cancer Association 18 The exclusion criteria 1 early gastric cancers 2 double primary malignancies 3 distant organ metastasis 4 loss follow 3 months surgery 5 treatment palliativenoncurative surgery Patients clinical histopathologic characteristics analyzed study acquired prospectively time surgery The Institutional Review Board hospital approved retrospective clinical study AN17196001 requirement informed consent waived All procedures performed study involving human participants accordance 1964 Helsinki declaration later amendments comparable ethical standards All patients underwent total subtotal gastrectomy according anatomic location primary tumor accompanied lymphadenectomy according General Rules httpsjgconlineorg httpsdoiorg105230jgc201818e23 219 LN FDG Avidity AGC Patients Gastric Cancer 18 Curative resection defined complete absence visible tumor tissue negative margins In cases subtotal gastrectomy tumorfree margins 3 cm 5 cm obtained patients wellmarginated infiltrative primary tumors respectively Histopathologic classification primary tumors included subtype signet ring cell vs nonsignet ring cell included adenocarcinoma papillary tubular poorly differentiated mucinous subtypes Lauren classification intestinal vs nonintestinal included diffuse mixed types Bormann classification After surgery patients underwent adjuvant chemotherapy based histopathologic results performance status Subsequently patients regularly followed serum tumor markers gastrofiberscopy andor CECT 18FFDG PETCT 18FFDG PETCT performed dedicated scanner Gemini TF 16 Philips Medical Systems Andover MA USA Patients fasted 6 hours blood glucose level 200 mgdL time 18FFDG injection PETCT image acquisition performed 60 minutes administration 18FFDG approximately 518 MBqkg A lowdose CT scan acquired attenuation correction 50 mA 120 kVp slice thickness 4 mm matrix size 512512 Emission PET images acquired 1 minute bed position PET images reconstructed 3dimensional iterative algorithm row action maximum likelihood algorithm TOF function 3 iterations 33 subsets matrix size 144144 Image analysis All 18FFDG PETCT images reviewed 2 experienced nuclear medicine physicians consensus 18FFDG avidity primary tumors LNs determined quantitative qualitative methods Quantitative parameters included maximum standardized uptake value SUVmax metabolic tumor volume MTV total lesion glycolysis TLG LNto tumor ratio LTR The SUVmax lesion measured volume VOI VOI primary tumor determined hottest point lesion transaxial PETCT images In case nondiscernible primary lesion PETCT VOI drawn stomach wall according tumor location based CECT gastrofiberscopy SUV calculated radioactivity kBq unit volume mLinjected 18FFDG activity kBq body mass g The MTV defined volume cm3 VOI The TLG calculated product MTV mean SUV VOI The ratio SUVmax LTR calculated The LTR nondiscernible LNs calculated coding SUVmax LNs 1 All image analyses performed dedicated workstation Extended Brilliance Workspace 40 Philips Healthcare Amsterdam The Netherlands Criteria determining 18FFDG avidity primary tumors LNs defined 1 focally increased 18FFDG uptake visual analysis 2 reasonable isocontouring result MTV cutoff value 50 SUVmax Fig 1 Clinicopathologic survival data Clinical data obtained medical records included age surgery sex preoperative serum carcinoembryonic antigen CEA histopathologic results pathologic T pT N pN staging Pathologic staging based 7th edition AJCC System Recurrence free survival RFS defined interval date surgery date cross sectional imaging recurrence pathologic confirmation clinical decision noted Overall survival OS defined interval date surgery date hospital visit httpsjgconlineorg httpsdoiorg105230jgc201818e23 220 LN FDG Avidity AGC Patients A CB 20 cm 25 cm C 20 cm Fig 1 Representative cases 18FFDGavid primary tumor A left LNs A right nonavid primary tumor B nonavid LN C The metabolic tumor volume primary tumor LNs patient A 188 cm3 02 cm3 respectively yellow arrow primary tumor red arrow LN 18FFDG 18Ffluorodeoxyglucose LN lymph node Statistical analyses Numeric data represented meanstandard deviation Differences variables groups compared Students ttest KruskalWallis test χ2 test Diagnostic performance 18FFDG avidity detecting primary tumors metastatic LNs evaluated calculating sensitivity specificity positive predictive value PPV negative predictive value NPV Survival time estimated logrank test Univariate Cox regression analysis performed evaluating statistical significance clinicopathologic parameters Continuous variables analyzed directly dichotomized optimal cutoff value receiver operating characteristics curve analysis Multivariate Cox regression analysis performed evaluate effect LNrelated parameters significant parameters Statistical analyses performed SPSS statistics software version 180 SPSS Inc Chicago IL USA P value 005 considered statistically significant RESULTS Patient characteristics Of 168 enrolled patients 51 304 experienced recurrence followup period median followup duration 35 months range 381 months 32 190 documented deaths Age sex operation type significantly different patients recurrence Table 1 The history adjuvant chemotherapy pT stage pN stage httpsjgconlineorg httpsdoiorg105230jgc201818e23 221 LN FDG Avidity AGC Patients Table 1 Patient characteristics Characteristics Age yr Male Extent gastric resection Total Subtotal Adjuvant Tx Yes No pT stage T2 T3 T4 pN stage N0 N1 N2 N3 TNM stage I II III Tumor size cm LVI Yes No Pathology Signet ring cell Nonsignet ring cell Lauren Intestinal Nonintestinal Bormann type 1 2 3 4 Total n168 6312 117 696 Recurrence n51 6113 31 607 No recurrence n117 6411 86 735 85 83 92 76 42 79 47 46 31 40 51 20 58 90 6029 121 47 14 154 86 79 6 20 117 20 29 22 38 13 1 21 29 4 4 12 31 0 5 46 7635 47 4 6 45 16 34 1 4 34 11 56 61 54 63 41 58 18 42 27 28 20 20 53 44 5323 74 43 8 109 70 45 5 16 83 9 P 0102 0161 0283 0001 0001 0001 0001 0001 0001 0288 0003 0062 Tx therapy pT pathologic tumor pN pathologic node TNM tumor node metastasis LVI lymphovascular invasion Three 5 unclassified TNM staging tumor size presence lymphovascular invasion LVI significantly different according recurrence P005 For histopathologic results frequency signet ring celltype significantly different according recurrence P0288 The frequency intestinaltype higher nonrecurring group P0003 However Bormann classification results vary significantly terms recurrence P0062 18FFDG avidity tumor lesions diagnostic evaluation We detected 18FFDGavid primary tumors 119 708 patients However presence 18FFDGavid primary tumors significantly different patients n37 725 n82 701 recurrence P0747 The SUVmax MTV TLG values 18FFDGavid primary tumors showed significant difference according recurrence P0561 0551 0800 respectively The SUVmax primary tumors including nonavid tumors showed difference patients recurrence 573426 vs 575508 P0979 We 33 196 patients showed 18FFDGavid LN 18FFDG PETCT 18FFDGavid LNs tended frequent recurring cases n14 275 nonrecurring cases n19 162 P0093 Similar httpsjgconlineorg httpsdoiorg105230jgc201818e23 222 LN FDG Avidity AGC Patients primary tumors SUVmax MTV TLG values 18FFDGavid LNs different patients recurrence P0854 0864 0661 respectively The calculated LTR significantly different patients recurrence 038026 vs 036029 P0749 The diagnostic evaluation 18FFDG PETCT high T stage pT 34 primary tumors showed sensitivity 738 specificity 381 PPV 782 NPV 327 Table 2 For detection high N stage pN 23 sensitivity specificity PPV NPV 18FFDG PETCT 297 922 818 526 respectively For detection metastatic LNs pN 13 sensitivity specificity PPV NPV 18FFDG PETCT 262 978 970 333 respectively Table 3 Prognostic factors RFS OS The median RFS OS 349 365 months respectively The significance 18FFDG avidity recurrence evaluated Fig 2 The 18FFDG avidity primary tumors significantly correlated RFS OS P0532 0658 respectively However 18FFDG avidity LNs showed significant correlation shorter RFS P0012 The mean RFS patients 18FFDGavid LNs 36545 months patients nonavid LNs 60427 months The relationship 18FFDG avidity LNs OS statistical significance P0181 Table 2 18FFDG avidity primary tumor according pT stage 18FFDG avidity 18FFDGavid Nonavid Total 18FFDG 18Ffluorodeoxyglucose pT pathologic tumor Table 3 18FFDG avidity metastatic LNs according pN stage 18FFDG avidity 18FFDGavid Nonavid Total 18FFDG 18Ffluorodeoxyglucose LN lymph node pT pathologic node pN0 1 45 46 Primary tumor A l v v r u S 10 08 06 04 02 Nonavid FDGavid pT2 26 16 42 pN1 5 26 31 B l v v r u S 10 08 06 04 02 Nonavid FDGavid Total 119 49 168 Total 33 135 168 pT34 93 33 126 pN23 27 64 91 LN 0 12 24 36 48 60 72 0 12 24 36 48 60 72 Time mo Time mo Fig 2 Cumulative RFS curve according 18FFDG avidity A primary tumors B LNs enrolled patients red nonavid group blue 18FFDGavid group RFS recurrencefree survival LN lymph node httpsjgconlineorg httpsdoiorg105230jgc201818e23 223 LN FDG Avidity AGC Patients Univariate analysis performed evaluate prognostic significance clinicopathologic parameters Table 4 Age sex correlated patients survival The size primary tumor number metastatic LNs proven histopathologically significantly correlated RFS OS P0001 High pT 3 pN 2 stages significantly correlated patients survival The histopathologic subtype signet ring cell cancer prognostic factor OS P0044 RFS P0377 Nonintestinal subtype LVI significant prognostic factors RFS OS Preoperative CEA level related RFS P0536 OS P0351 18FFDG avidity primary tumors correlated RFS OS 18FFDG avidity LNs significant prognostic factor RFS P0015 The correlation 18FFDG avidity LNs OS significant P0187 Other 18FFDGPETCTdriven parameters including SUVmax primary tumors LTR significantly correlated patients survival Construction multivariate survival models based significant parameters driven univariate analysis metastatic LNrelated parameters combined compare effect model 1 Model 18FFDG avidity LNs 2 Model number metastatic LNs 3 Model pN stage 2 Tables 5 6 For RFS size primary tumor independent prognostic factor models Table 5 Nonintestinal subtype LVI independent factors models 1 2 significance observed model 3 18FFDG avidity LNs independent prognostic factor predicting RFS For OS size primary tumor independent prognostic factor models Table 6 Table 4 Univariate Cox regression analysis prognostic factors related survival Variables Age 65 yr Sex male Tumor size Number metastatic LNs pT stage 3 pN stage 2 Histopathology signet ring cell Lauren nonintestinal LVI yes CEA Primary tumor 18FFDG avidity LN 18FFDG avidity SUVmax primary tumor 44 LTR SUVmax 03 RFS recurrencefree survival OS overall survival HR hazard ratio CI confidence interval LN lymph node pT pathologic tumor pN pathologic node LVI lymphovascular invasion CEA carcinoembryonic antigen 18FFDG 18Ffluorodeoxyglucose SUVmax maximum standardized uptake value LTR lymph nodetotumor ratio HR 0745 0656 1215 1054 24206 6665 1468 2728 6133 0999 1217 2165 1316 0911 P 0507 0696 0001 0001 0013 0001 0044 0036 0008 0351 0659 0187 0107 0526 P 0302 0146 0001 0001 0002 0001 0377 0001 0001 0536 0533 0015 0328 0741 HR 0787 1173 1213 1042 4527 8293 2495 2216 5057 0936 1190 1724 1789 0798 RFS 95 CI 04261303 03721159 11291309 10371072 3331175887 311714249 06263442 15044948 220417067 09951003 06572254 11644025 07592281 05261580 OS 95 CI 03881596 05272614 11071329 10171067 137214943 289823735 10276064 10524644 153416673 08131076 05502575 07683868 08833626 03981602 Table 5 Multivariate Cox regression models RFS Variables Model LN avidity Model LN number Model pN stage P 0002 Size 0054 Lauren nonintestinal 0228 LVI LN 18FFDG avidity NA NA Number metastatic LNs pN stage 0015 RFS recurrencefree survival LN lymph node pN pathologic node HR hazard ratio CI confidence interval LVI lymphovascular invasion 18FFDG 18Ffluorodeoxyglucose NA assessed HR 95 CI 1158 10711252 2378 12524517 3704 127810741 1964 10123811 HR 95 CI 1125 10431215 1861 09903498 2099 06306998 HR 95 CI 1114 10281208 1946 10303677 3657 127310505 P 0001 0005 0017 0046 NA NA P 0009 0040 0016 NA 0011 NA 1027 10061048 3128 12517818 httpsjgconlineorg httpsdoiorg105230jgc201818e23 224 LN FDG Avidity AGC Patients Table 6 Multivariate Cox regression models OS Variables Model LN avidity Model LN number Model pN stage HR 95 CI 1170 10541300 0337 06433639 3063 087110780 2202 08265871 1702 06944174 Size Lauren nonintestinal LVI Histopathology signet ring cell LN 18FFDG avidity Number metastatic LNs pN stage OS overall survival LN lymph node pN pathologic node HR hazard ratio CI confidence interval LVI lymphovascular invasion 18FFDG 18Ffluorodeoxyglucose NA assessed 4862 122019373 1014 09841045 HR 95 CI 1130 10171255 1163 05062675 1210 02615611 1979 07495228 HR 95 CI 1149 10301282 1304 05623027 3217 092811149 2175 08145813 P 0003 0337 0081 0115 0245 NA NA P 0013 0537 0065 0121 NA 0365 NA P 0023 0722 0807 0168 NA NA 0025 Other histopathologic factors statistical significance Among LNrelated parameters pN stage independent factor predicting OS Subgroup analysis performed patients histopathologically proven adenocarcinoma n154 histologic grade primary tumor added survival analysis As total patient population tumor size number metastatic LNs pathologic staging LVI showed significance predicting RFS OS Supplementary Table 1 Poorly differentiated subtype significant prognostic factor RFS P0005 OS P0175 Lauren nonintestinal subtype significant factor RFS P0001 OS P0137 The 18FFDG avidity LNs significant factor RFS univariate analysis P0031 multivariate analysis P0120 Supplementary Table 2 DISCUSSION This study evaluated diagnostic prognostic value preoperative 18FFDG PETCT patients resectable AGC Current evidence suggests primary tumor resection standardized D2 lymphadenectomy best postoperative care lower recurrence death rate morbiditymortality 19 Standardized preoperative workup recommended evaluate disease status based patient examination laboratory profile endoscopy procedure CECT 7 However 5year survival rate curative resection remains disappointing Randomized clinical trials reported varying results adjuvant chemotherapy according regional differences 2021 These findings suggest heterogeneous biology gastric cancer need effective prognostic biomarkers AGC patients 22 Evaluation tumor metabolism 18FFDG PETCT play potential role surrogate marker tumor aggressiveness correlated patients prognoses The diagnosis LN metastasis important prognostic factors AGC patients curative surgery 23 LN metastasis predicts accurate stagespecific survival subclassification patients similar pT stage 24 The number metastatic LNs directly correlated survival time 25 Hence comprehensive analysis LN metastasis needed evaluate AGC patients especially contemplating curative surgery Endoscopic ultrasonography showed high predictive value approximately 926 nodenegative early gastric cancer played limited role predicting extraperigastric LN metastasis 2627 CECT widely evaluation degree LN metastasis size criteria determining LN metastasis limited sensitivity yield falsenegative results 28 The diagnostic accuracy preoperative 18FFDG PETCT LN metastasis patients AGC long discussed The httpsjgconlineorg httpsdoiorg105230jgc201818e23 225 LN FDG Avidity AGC Patients diagnostic sensitivity metastasis N1 LNs 50 lower CECT However 18FFDG PETCT outperformed CECT specificity N staging Especially advanced N stage specificity 18FFDG PETCT 96 99 N2 N3 lymph nodes respectively 2931 In view resectability accurate staging advanced disease essential planning surgical approach extent en bloc resection This study showed comparable accuracy high specificity 922 diagnosis advanced N stage 18FFDG avidity LNs determined combining qualitative quantitative criteria We suggest diagnostic value 18FFDG PETCT related directly prognostic information determine patients survival Until studies reported correlation 18FFDG uptake LNs prognoses patients AGC A recent study revealed high SUVmax LNs independent factor patients RFS OS 15 Metabolic information LNs correlated patients OS size lymphadenopathies significant relationship Additionally 18FFDG PETCT revealed metastatic disease detected CT 32 In study 18FFDG avidity LNs patients AGC significantly correlated disease recurrence histopathologic parameters determining metastatic LNs Patients nonavid LNs 2year RFS rate 822 111135 patients 18FFDGavid LNs showed 2year RFS rate 606 2033 The mean difference RFS according 18FFDG avidity LNs approximately 24 months The results suggest need revisiting role preoperative 18FFDG PETCT accurate prediction recurrence patients AGC Studies evaluating utility 18FFDG PETCT AGC focused 18FFDG uptake primary tumors High 18FFDG uptake primary tumors associated 2year RFS curative resection 3334 In study 18FFDG avidity primary tumors significantly correlated recurrence 18FFDG uptake primary tumors partly affected background gastric wall activity histopathologic subtype 35 Furthermore parameters measuring 18FFDG uptake primary tumors proposed including SUVmax MTV tumortoliver ratio 1136 Further studies optimizing 18FFDG PET CTdriven parameters needed investigate correlation glucose metabolism gastric cancer patients prognoses In present study 18FFDG avidity LNs determined dichotomously instead continuous SUVmax values The SUVmax small perigastric LNs hard standardize partialvolume effect spill effect 37 18FFDG avidity LNs study high specificity determining nodal metastases represents independent prognostic factor RFS This study limitations First 18FFDG avidity LNs correlated patients RFS OS probably relatively small sample event size Second prognosispredicting model study entirely based preoperative clinical parameters Further studies needed evaluate significance preoperative 18FFDG PETCT terms clinical staging Finally retrospective singlecenter study inevitably associated patient selection bias In conclusion study demonstrates 18FFDG avidity LNs evaluated PETCT scan independent factor contributing RFS following curative resection patients AGC We suggest preoperative 18FFDG PETCT predicting prognosis aimed appropriate risk monitoring AGC patients followup surgery httpsjgconlineorg httpsdoiorg105230jgc201818e23 226 LN FDG Avidity AGC Patients SUPPLEMENTARY MATERIALS Supplementary Table 1 Univariate Cox regression analysis prognostic factors related survival subgroup analysis Click view Supplementary Table 2 Multivariate Cox regression models RFS subgroup analysis Click view REFERENCES 1 Jung KW Won YJ Oh CM Kong HJ Lee DH Lee KH et al Cancer statistics Korea incidence mortality survival prevalence 2014 Cancer Res Treat 201749292305 PUBMED CROSSREF 2 Katanoda K Hori M Matsuda T Shibata A Nishino Y Hattori M et al An updated report trends cancer incidence mortality Japan 19582013 Jpn J Clin Oncol 201545390401 PUBMED CROSSREF 3 Siegel RL Miller KD Jemal A Cancer statistics 2016 CA Cancer J Clin 201666730 PUBMED CROSSREF 4 Maehara Y Hasuda S Koga T Tokunaga E Kakeji Y Sugimachi K Postoperative outcome sites recurrence patients following curative resection gastric cancer Br J Surg 200087353357 PUBMED CROSSREF 5 Deng N Goh LK Wang H Das K Tao J Tan IB et al A comprehensive survey genomic alterations gastric cancer reveals systematic patterns molecular exclusivity cooccurrence distinct therapeutic targets Gut 201261673684 PUBMED CROSSREF 6 Dulak AM Schumacher SE van Lieshout J Imamura Y Fox C Shim B et al Gastrointestinal adenocarcinomas esophagus stomach colon exhibit distinct patterns genome instability oncogenesis Cancer Res 20127243834393 PUBMED CROSSREF 7 Ajani JA DAmico TA Almhanna K Bentrem DJ Chao J Das P et al Gastric cancer version 32016 NCCN clinical practice guidelines oncology J Natl Compr Canc Netw 20161412861312 PUBMED CROSSREF 8 Smyth EC Verheij M Allum W Cunningham D Cervantes A Arnold D et al Gastric cancer ESMO clinical practice guidelines diagnosis treatment followup Ann Oncol 201627v38v49 PUBMED CROSSREF 9 Smyth E Schöder H Strong VE Capanu M Kelsen DP Coit DG et al A prospective evaluation utility 2deoxy218FfluoroDglucose positron emission tomography computed tomography staging locally advanced gastric cancer Cancer 201211854815488 PUBMED CROSSREF 10 Baiocchi GL Marrelli D Verlato G Morgagni P Giacopuzzi S Coniglio A et al Followup gastrectomy cancer appraisal Italian research group gastric cancer Ann Surg Oncol 20142120052011 PUBMED CROSSREF 11 Lee JW Jo K Cho A Noh SH Lee JD Yun M Relationship 18FFDG uptake PET recurrence patterns curative surgical resection patients advanced gastric cancer J Nucl Med 20155614941500 PUBMED CROSSREF 12 Lordick F Ott K Krause BJ Weber WA Becker K Stein HJ et al PET assess early metabolic response guide treatment adenocarcinoma oesophagogastric junction MUNICON phase II trial Lancet Oncol 20078797805 PUBMED CROSSREF httpsjgconlineorg httpsdoiorg105230jgc201818e23 227 LN FDG Avidity AGC Patients 13 Ott K Weber WA Lordick F Becker K Busch R Herrmann K et al Metabolic imaging predicts response survival recurrence adenocarcinomas esophagogastric junction J Clin Oncol 20062446924698 PUBMED CROSSREF 14 Washington K 7th edition AJCC cancer staging manual stomach Ann Surg Oncol 20101730773079 PUBMED CROSSREF 15 Song BI Kim HW Won KS Ryu SW Sohn SS Kang YN Preoperative standardized uptake value metastatic lymph nodes measured 18FFDG PETCT improves prediction prognosis gastric cancer Medicine Baltimore 201594e1037 PUBMED CROSSREF 16 Cerfolio RJ Bryant AS Ratio maximum standardized uptake value FDGPET mediastinal N2 lymph nodes primary tumor universal predictor nodal malignancy patients nonsmallcell lung cancer Ann Thorac Surg 20078318261830 PUBMED CROSSREF 17 Park J Byun BH Noh WC Lee SS Kim HA Kim EK et al Lymph node primary tumor SUV ratio 18FFDG PETCT prediction axillary lymph node metastases breast cancer Clin Nucl Med 201439e249e253 PUBMED CROSSREF 18 Japanese Gastric Cancer Association Japanese classification gastric carcinoma 3rd English edition Gastric Cancer 201114101112 PUBMED CROSSREF 19 Songun I Putter H Kranenbarg EM Sasako M van Velde CJ Surgical treatment gastric cancer 15 year followup results randomised nationwide Dutch D1D2 trial Lancet Oncol 201011439449 PUBMED CROSSREF 20 Ajani JA Rodriguez W Bodoky G Moiseyenko V Lichinitser M Gorbunova V et al Multicenter phase III comparison cisplatinS1 cisplatininfusional fluorouracil advanced gastric gastroesophageal adenocarcinoma study FLAGS trial J Clin Oncol 20102815471553 PUBMED CROSSREF 21 Sakuramoto S Sasako M Yamaguchi T Kinoshita T Fujii M Nashimoto A et al Adjuvant chemotherapy gastric cancer S1 oral fluoropyrimidine N Engl J Med 200735718101820 PUBMED CROSSREF 22 Abbas M Habib M Naveed M Karthik K Dhama K Shi M et al The relevance gastric cancer biomarkers prognosis pre post chemotherapy clinical practice Biomed Pharmacother 20179510821090 PUBMED CROSSREF 23 Deng JY Liang H Clinical significance lymph node metastasis gastric cancer World J Gastroenterol 20142039673975 PUBMED CROSSREF 24 Sarela AI Turnbull AD Coit DG Klimstra D Brennan MF Karpeh MS Accurate lymph node staging greater prognostic importance subclassification T2 category gastric adenocarcinoma Ann Surg Oncol 200310783791 PUBMED CROSSREF 25 Ichikura T Tomimatsu S Okusa Y Uefuji K Tamakuma S Comparison prognostic significance number metastatic lymph nodes nodal stage based location patients gastric cancer J Clin Oncol 19931118941900 PUBMED CROSSREF 26 Ahn HS Lee HJ Yoo MW Kim SG Im JP Kim SH et al Diagnostic accuracy T N stages endoscopy stomach protocol CT endoscopic ultrasonography early gastric cancer J Surg Oncol 2009992027 PUBMED CROSSREF 27 Hwang SW Lee DH Is endoscopic ultrasonography modality choice preoperative staging gastric cancer World J Gastroenterol 2014201377513782 PUBMED CROSSREF 28 Kim SH Kim JJ Lee JS Kim SH Kim BS Maeng YH et al Preoperative N staging gastric cancer stomach protocol computed tomography J Gastric Cancer 201313149156 PUBMED CROSSREF 29 Kim SK Kang KW Lee JS Kim HK Chang HJ Choi JY et al Assessment lymph node metastases 18FFDG PET patients advanced gastric cancer Eur J Nucl Med Mol Imaging 200633148155 PUBMED CROSSREF httpsjgconlineorg httpsdoiorg105230jgc201818e23 228 LN FDG Avidity AGC Patients 30 Kim EY Lee WJ Choi D Lee SJ Choi JY Kim BT et al The value PETCT preoperative staging advanced gastric cancer comparison contrastenhanced CT Eur J Radiol 201179183188 PUBMED CROSSREF 31 Yun M Lim JS Noh SH Hyung WJ Cheong JH Bong JK et al Lymph node staging gastric cancer 18FFDG PET comparison study CT J Nucl Med 20054615821588 PUBMED 32 Coupe NA Karikios D Chong S Yap J Ng W Merrett N et al Metabolic information staging FDGPETCT prognostic tool evaluation 97 patients gastric cancer Ann Nucl Med 201428128135 PUBMED CROSSREF 33 Lee JW Lee SM Lee MS Shin HC Role 18FFDG PETCT prediction gastric cancer recurrence curative surgical resection Eur J Nucl Med Mol Imaging 20123914251434 PUBMED CROSSREF 34 Mochiki E Kuwano H Katoh H Asao T Oriuchi N Endo K Evaluation 18F2deoxy2fluoroDglucose positron emission tomography gastric cancer World J Surg 200428247253 PUBMED CROSSREF 35 Stahl A Ott K Weber WA Becker K Link T Siewert JR et al FDG PET imaging locally advanced gastric carcinomas correlation endoscopic histopathological findings Eur J Nucl Med Mol Imaging 200330288295 PUBMED CROSSREF 36 Kim J Lim ST Na CJ Han YH Kim CY Jeong HJ et al Pretreatment F18 FDG PETCT parameters evaluate progressionfree survival gastric cancer Nucl Med Mol Imaging 2014483340 PUBMED CROSSREF 37 Soret M Bacharach SL Buvat I Partialvolume effect PET tumor imaging J Nucl Med 200748932945 PUBMED CROSSREF httpsjgconlineorg httpsdoiorg105230jgc201818e23 229